S-1: Dror Ortho-Design Files for Resale of Over 2.3 Billion Shares Following Share Exchange

Dror Ortho-Design registers for the resale of over 2.3 billion shares of common stock by selling securityholders after completing a share exchange and private placement.

Summary

• Dror Ortho-Design, Inc. has filed a registration statement for the resale of 2,304,316,461 shares of common stock.
• These shares are held by selling securityholders and include shares issued in a private placement and to former shareholders of Private Dror in connection with a share exchange.
• The filing also covers shares issuable upon conversion of Series A Convertible Preferred Stock and upon exercise of private placement warrants and share exchange warrants.
• The company will not receive any proceeds from the sale of these shares by the selling securityholders.
• Dror Ortho-Design intends to use any proceeds from the exercise of warrants for general corporate purposes.
• The company's common stock is currently quoted on the OTC Pink Market under the symbol DROR.
• The last reported sales price for the common stock was $0.0193 per share on February 8, 2024.
• The company completed a share exchange with Dror Ortho-Design Ltd. on August 14, 2023, and changed its name accordingly.
• In connection with the share exchange, the company sold shares of common stock and Series A Preferred Stock and Private Placement Warrants in a private placement, raising $5,025,000 in the first closing and an additional $200,000 in a subsequent closing.

Sentiment

Score: 5

Explanation: The document is neutral, primarily focused on factual information regarding the share registration and company structure. The risks are balanced with potential opportunities.

Positives

• The registration allows selling securityholders to resell their shares, potentially increasing liquidity.
• The company may receive proceeds from the exercise of warrants, which it intends to use for general corporate purposes.
• The completion of the share exchange and private placement provides the company with additional capital and a new line of business.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling securityholders.
• The company's stock trades on the OTC Pink Market, which may indicate limited liquidity and higher volatility.
• The company is in the development stage and is not generating revenues.

Risks

• The company is in the development stage and is not generating revenues.
• The company's stock trades on the OTC Pink Market, which may indicate limited liquidity and higher volatility.
• The company faces competition from large, established aligner companies.
• The company's success depends on its ability to obtain regulatory clearance for its platform.
• The company's operations are subject to economic, political, and military conditions in Israel.

Future Outlook

The company intends to continually improve and enhance its platform and/or develop and introduce new products and services in order to maintain or increase its sales.

Industry Context

The company aims to disrupt the aligner market by offering a revolutionary alternative to traditional aligner solutions, leveraging advancements in technology and AI.

Comparison to Industry Standards

• The document mentions Invisalign clear aligners solution provided by Align Technology, Inc. as a comparable product.
• Clinical trials demonstrated that Aerodentis System was suitable for adults and pediatric patients with Class 1 and Class 2 malocclusion, including crowding, proclination and retroclination.
• Further, clinical trials have demonstrated that the effectiveness of Aerodentis System was consistent with the results achieved by the Invisalign clear aligners solution provided by Align Technology, Inc.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's employees may benefit from the equity incentive plan.
• Customers may benefit from the company's innovative orthodontic solutions.

Next Steps

• The selling securityholders may offer or sell the shares of common stock from time to time through public or private transactions.
• The company intends to apply to have its common stock listed for trading on The Nasdaq Stock Market.
• The company is preparing to apply for 510(k) clearance for the updated version of the currently cleared device.

Key Dates

Keywords

common stock, share exchange, private placement, warrants, Dror Ortho-Design, resale, Series A Preferred Stock, OTC Pink Market, registration statement, securityholders